Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.

Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab. Dermatol Online J. 2019 Dec 15;25(12): Authors: Gracia-Cazaña T, Padgett E, Hernández-García A, Sánchez-Salas MP Abstract Anti-programmed cell death (PD)-1 therapies in metastatic tumors have a high incidence of immune adverse events, including cutaneous manifestations such as vitiligo-like lesions. This side effect is associated with increased survival and it is a clinical marker of response to treatment. This case report is a graphic representation of the appearance of vitiligo-like lesions over in-transit metastases of malignant melanoma linked to a complete response to treatment with pembrolizumab. PMID: 32045170 [PubMed - in process]
Source: Dermatol Online J - Category: Dermatology Authors: Tags: Dermatol Online J Source Type: research